SG10201804954UA - Methods for treating psoriasis using an anti-il-23 antibody - Google Patents

Methods for treating psoriasis using an anti-il-23 antibody

Info

Publication number
SG10201804954UA
SG10201804954UA SG10201804954UA SG10201804954UA SG10201804954UA SG 10201804954U A SG10201804954U A SG 10201804954UA SG 10201804954U A SG10201804954U A SG 10201804954UA SG 10201804954U A SG10201804954U A SG 10201804954UA SG 10201804954U A SG10201804954U A SG 10201804954UA
Authority
SG
Singapore
Prior art keywords
antibody
methods
treating psoriasis
psoriasis
products
Prior art date
Application number
SG10201804954UA
Inventor
John Gibbs
Wayne Tsuji
Wei-Jian Pan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50336511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201804954U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG10201804954UA publication Critical patent/SG10201804954UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)

Abstract

METHODS FOR TREATING PSORIASIS USING AN ANTI-IL- ANTIBODY The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double- blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis. [Figure 11] 28
SG10201804954UA 2013-03-15 2014-02-25 Methods for treating psoriasis using an anti-il-23 antibody SG10201804954UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361789777P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
SG10201804954UA true SG10201804954UA (en) 2018-07-30

Family

ID=50336511

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201507482UA SG11201507482UA (en) 2013-03-15 2014-02-25 Methods for treating psoriasis using an anti-il-23 antibody
SG10201804954UA SG10201804954UA (en) 2013-03-15 2014-02-25 Methods for treating psoriasis using an anti-il-23 antibody

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201507482UA SG11201507482UA (en) 2013-03-15 2014-02-25 Methods for treating psoriasis using an anti-il-23 antibody

Country Status (17)

Country Link
US (3) US20160060337A1 (en)
EP (2) EP2968488A1 (en)
JP (4) JP2016517408A (en)
KR (1) KR20150128858A (en)
CN (1) CN105209064A (en)
AP (1) AP2015008803A0 (en)
AU (3) AU2014238148A1 (en)
CA (1) CA2906382A1 (en)
CL (1) CL2015002723A1 (en)
CR (1) CR20150572A (en)
EA (1) EA201591581A1 (en)
HK (1) HK1219425A1 (en)
IL (2) IL241342A0 (en)
PH (2) PH12015502129A1 (en)
SG (2) SG11201507482UA (en)
TN (1) TN2015000403A1 (en)
WO (1) WO2014149425A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2635601T (en) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anti-il-23 antibodies
EP2844284A1 (en) 2012-05-03 2015-03-11 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (en) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Compound targeting il-23a and tnf-alpha and uses thereof
EP3253794A1 (en) * 2015-02-04 2017-12-13 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
CA3019164A1 (en) * 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
EP3824295A4 (en) * 2018-07-18 2022-04-27 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
BR112021008582A8 (en) * 2018-11-05 2023-02-07 Merck Sharp & Dohme ANTI-TIGIT ANTIBODY DOSAGE REGIME FOR CANCER TREATMENT
US20200331996A1 (en) * 2019-03-18 2020-10-22 Janssen Biotech, Inc. Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PE20000183A1 (en) 1997-07-25 2000-03-11 Schering Corp MAMMAL CYTOKINES AND RELATED REAGENTS
CN101252951B (en) 2005-06-30 2011-12-21 森托科尔公司 Anti-IL-23 antibodies, compositions, methods and uses
PL1937721T3 (en) 2005-08-25 2010-12-31 Lilly Co Eli Anti-il-23 antibodies
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
EP1931710B1 (en) 2005-08-31 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
US20090270480A1 (en) * 2005-12-28 2009-10-29 Bernard Amegadzie Markers and Methods for Assessing and Treating Psoriasis and Related Disorders
LT2548577T (en) 2005-12-29 2017-04-10 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
MX2009009079A (en) 2007-02-23 2009-08-31 Schering Corp Engineered anti-il-23p19 antibodies.
CN101663320A (en) * 2007-02-23 2010-03-03 先灵公司 engineered anti-il-23p19 antibodies
AR068723A1 (en) 2007-10-05 2009-12-02 Glaxo Group Ltd PROTEIN THAT JOINS ANTIGENS THAT JOINS HUMAN IL-23 AND ITS USES
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA2717569A1 (en) * 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
EP2301119B1 (en) 2008-06-30 2015-05-13 Black & Decker, Inc. Cord protector for power tools
AU2009288419B2 (en) 2008-08-27 2015-08-06 Merck Sharp & Dohme Llc Lyophilized formulatons of engineered anti-IL-23p19 antibodies
JP2012522749A (en) 2009-04-01 2012-09-27 グラクソ グループ リミテッド Anti-IL-23 immunoglobulin
EP2435480A1 (en) 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
JO3244B1 (en) 2009-10-26 2018-03-08 Amgen Inc Human il-23 antigen binding proteins
HUE035618T2 (en) 2010-01-15 2018-05-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
MX341309B (en) 2010-07-20 2016-08-12 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies.
BR112013008528A2 (en) * 2010-10-06 2019-09-24 Abbvie Inc Methods To Treat Psoriasis
LT2625199T (en) * 2010-10-08 2018-03-12 Novartis Ag Methods of treating psoriasis using il-17 antagonists
PT2635601T (en) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anti-il-23 antibodies

Also Published As

Publication number Publication date
IL241342A0 (en) 2015-11-30
PH12015502129A1 (en) 2016-01-25
JP2016517408A (en) 2016-06-16
TN2015000403A1 (en) 2017-01-03
JP2020063237A (en) 2020-04-23
CL2015002723A1 (en) 2016-03-28
AU2019200206A1 (en) 2019-01-31
EP3689369A1 (en) 2020-08-05
CR20150572A (en) 2016-04-25
SG11201507482UA (en) 2015-10-29
AU2020270495A1 (en) 2020-12-17
IL275093A (en) 2020-07-30
AU2014238148A1 (en) 2015-10-08
KR20150128858A (en) 2015-11-18
EP2968488A1 (en) 2016-01-20
CA2906382A1 (en) 2014-09-25
PH12019502700A1 (en) 2020-12-07
EA201591581A1 (en) 2016-01-29
US20220135668A1 (en) 2022-05-05
JP2023011815A (en) 2023-01-24
AP2015008803A0 (en) 2015-10-31
US20160060337A1 (en) 2016-03-03
CN105209064A (en) 2015-12-30
US20200277368A1 (en) 2020-09-03
HK1219425A1 (en) 2017-04-07
JP2021102644A (en) 2021-07-15
WO2014149425A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
PH12019502700A1 (en) Methods for treating psoriasis using an anti-il-23 antibody
PH12015502133A1 (en) Methods for treating crohn's disease using an anti-il23 antibody
MX2022009538A (en) Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects.
MY187540A (en) Compounds active towards bromodomains
PH12015500196A1 (en) Methods of treating a tauopathy
MX2019015604A (en) Methods of treating a tauopathy.
PH12017501659A1 (en) Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk
EA036102B9 (en) Glycotargeting therapeutics
MX2015012379A (en) Novel lactobacillus strains and the uses thereof.
MX2017001638A (en) Carrier molecule for antigens.
MX2022005469A (en) Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease.
MX2018005825A (en) Modified immune cells and uses thereof.
MX2019003703A (en) Safe and effective method of treating psoriasis with anti-il23 specific antibody.
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
BR112018014723A2 (en) bacterial ghosts for cancer treatment
MX2022014763A (en) Compositions of grapiprant and methods for using the same.
BR112016002619A2 (en) BAG3 RECEPTOR BINDING MOLECULES FOR USE AS A MEDICINE
BR112015025697A2 (en) mutant vaccinia virus strain, use of the mutant vaccinia virus strain, method for producing a recombinant gene product and recombinant gene product
MX2020002585A (en) Hdac inhibitor in combination with immune checkpoint modulator for cancer therapy.
PH12018502139A1 (en) Phosphaplatin liquid formulations
PH12017501979A1 (en) Pharmaceutical compound
AR097179A1 (en) TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND FLUPIRTINE
MX2017001512A (en) Compounds active towards bromodomains.
UA103888U (en) Phenol solution for injection for treatment of chronic pain syndrome
GR1008586B (en) Preparation of extremely small-sized uniform hyper-magnetic maghemite nanoparticles for use as a contrast medium in ct and mri scans